{
  "docId": "019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "docSlug": "5e172cf8223e03a5f49c2e34f7f0a14c",
  "documentTitle": "Valneva | IPO Presentation Deck | 41 slides",
  "authorId": "valneva",
  "authorName": "Valneva",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4117647,
  "pageNumber": 29,
  "pageCount": 41,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes statistical analysis of antibody titers across different dose groups over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-f16a-77fb-9c90-c741a7f6a0f0/29",
  "deckHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0",
  "deckJsonHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0.json",
  "deckAnchorHref": "/decks/019de070-f16a-77fb-9c90-c741a7f6a0f0#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.25,
        "x": 0.58,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Plot of SARS-CoV-2 Neutralizing Antibodies (ND50) for Convalescent Sera",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "582ffa44-b926-42b9-91fd-4c9043d352a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.5,
        "x": 0.06,
        "y": 0.18
      },
      "kind": "chart",
      "text": "Plot of SARS-CoV-2 Neutralizing Antibodies (ND50) Over Time by Dose Groups",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "591dbad8-c274-4782-9266-790f8b0944b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.06,
        "y": 0.7
      },
      "kind": "list",
      "text": "Dose dependent response, statistically significant higher Geometric Mean Titers (GMTs) in high dose group compared to low and medium dose groups. In high dose group, GMT of neutralizing antibody titers of 530.4 (95% CI: 421.49, 667.52). With a GMT ratio of vaccine vs. convalescent sera ≥ 1 vaccine efficacy has been reported above 80% for other vaccines.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28b1ce02-aedd-4da2-a725-a50348196181",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.06,
        "y": 0.06
      },
      "kind": "title",
      "text": "VLA2001 Generated Neutralizing Antibody Titers at or Above Levels Generally Seen in Convalescent Sera in Phase 1/2",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c77cedb-2877-4f50-922b-38be96a1b6c3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "9b4fd6d6-eb8b-4b3c-8e6b-20619681ae33",
      "evidence": "chart/dot: Plot of SARS-CoV-2 Neutralizing Antibodies (ND50) Over Time by Dose Groups",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}